Hydrocortisone plus fludrocortisone crossover trial
Blockmans D et al. · 2003 · American Journal of Medicine
Indexed 2026-11-12.
Reported findings and study design
Reported findings
Six-month double-blind placebo-controlled crossover trial. The active combination used hydrocortisone 5 mg/day and fludrocortisone 50 μg/day.
Dose, route and schedule
Six-month double-blind placebo-controlled crossover trial. The active combination used hydrocortisone 5 mg/day and fludrocortisone 50 μg/day.
Protocol source ↗ · Original article abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Fatigue and well-being | The combination did not improve fatigue or well-being versus placebo. |
The result applies to this combined regimen and historical case definition.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- The result applies to this combined regimen and historical case definition.
Source access
Six-month double-blind placebo-controlled crossover trial. The active combination used hydrocortisone 5 mg/day and fludrocortisone 50 μg/day.
Source reviewed 2026-11-12.
Citation and original source
Original source: Blockmans D et al.. Hydrocortisone plus fludrocortisone crossover trial American Journal of Medicine 2003.
Molekul research summary: https://molekul.io/research/hydrocortisone-fludrocortisone-cfs-2003. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry